Nas­daq pa­rade march­es on as ex-Gen­mab crew at Y-mAbs reaps $96M

The sto­ry that Y-mAbs told for the first time in its IPO fil­ing has earned the can­cer biotech an up­sized $92 mil­lion raise to pow­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.